ATE538800T1 - Kombinationstherapie zur krebsbehandlung - Google Patents

Kombinationstherapie zur krebsbehandlung

Info

Publication number
ATE538800T1
ATE538800T1 AT07119706T AT07119706T ATE538800T1 AT E538800 T1 ATE538800 T1 AT E538800T1 AT 07119706 T AT07119706 T AT 07119706T AT 07119706 T AT07119706 T AT 07119706T AT E538800 T1 ATE538800 T1 AT E538800T1
Authority
AT
Austria
Prior art keywords
combination therapy
cancer treatment
effective amount
combination
cancer
Prior art date
Application number
AT07119706T
Other languages
English (en)
Inventor
Bharvin Patel
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE538800T1 publication Critical patent/ATE538800T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT07119706T 2004-04-22 2005-04-15 Kombinationstherapie zur krebsbehandlung ATE538800T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US56454004P 2004-04-22 2004-04-22

Publications (1)

Publication Number Publication Date
ATE538800T1 true ATE538800T1 (de) 2012-01-15

Family

ID=35094133

Family Applications (2)

Application Number Title Priority Date Filing Date
AT05738307T ATE401088T1 (de) 2004-04-22 2005-04-15 Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs
AT07119706T ATE538800T1 (de) 2004-04-22 2005-04-15 Kombinationstherapie zur krebsbehandlung

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT05738307T ATE401088T1 (de) 2004-04-22 2005-04-15 Zusammensetzung mit einem survivin-antisense- oligonucleotid und gemcitabin zur behandlung von krebs

Country Status (17)

Country Link
US (3) US20070244065A1 (de)
EP (3) EP1763356B1 (de)
JP (1) JP2007533742A (de)
CN (2) CN101683355A (de)
AT (2) ATE401088T1 (de)
AU (1) AU2005240020B2 (de)
BR (1) BRPI0509927A (de)
CA (1) CA2562750A1 (de)
CY (2) CY1110440T1 (de)
DE (1) DE602005008241D1 (de)
DK (2) DK1763356T3 (de)
ES (2) ES2308488T3 (de)
MX (1) MXPA06012132A (de)
PL (2) PL1763356T3 (de)
PT (2) PT1913947E (de)
SI (2) SI1913947T1 (de)
WO (1) WO2005107771A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2310006A4 (de) * 2008-07-03 2012-04-25 Mayo Foundation Krebsbehandlung
FR2955112B1 (fr) 2010-01-14 2012-01-20 Isp Investments Inc Nouveaux peptides anti-age modulateurs de la survivine et compositions les comprenant
WO2012058462A2 (en) * 2010-10-29 2012-05-03 Isis Pharmaceuticals, Inc. Combination therapy for the treatment of cancer
AU2012253571A1 (en) 2011-05-09 2014-01-09 Mayo Foundation For Medical Education And Research Cancer treatments
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
EP3154586B1 (de) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Behandlung von lymphomen
KR20170020371A (ko) 2014-06-16 2017-02-22 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 골수종의 치료
US9446148B2 (en) 2014-10-06 2016-09-20 Mayo Foundation For Medical Education And Research Carrier-antibody compositions and methods of making and using the same
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
WO2017120501A1 (en) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Methods of treating cancer with interferon
WO2017139698A1 (en) 2016-02-12 2017-08-17 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (de) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Verfahren zur verbesserung des therapeutischen index für ein chemotherapeutikum
EP3432926A4 (de) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Verfahren zur verminderung der toxizität eines chemotherapeutikums
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018045239A1 (en) 2016-09-01 2018-03-08 Mayo Foundation For Medical Education And Research Carrier-pd-l1 binding agent compositions for treating cancers
JP2019526579A (ja) 2016-09-01 2019-09-19 マヨ ファウンデーション フォー メディカル エデュケーション アンド リサーチＭａｙｏ Ｆｏｕｎｄａｔｉｏｎ Ｆｏｒ Ｍｅｄｉｃａｌ Ｅｄｕｃａｔｉｏｎ Ａｎｄ Ｒｅｓｅａｒｃｈ Ｔ細胞癌を標的とする為の方法及び組成物
KR20230011473A (ko) 2016-09-06 2023-01-20 메이오 파운데이션 포 메디칼 에쥬케이션 앤드 리써치 Ｐｄ－ｌ１ 발현 암의 치료 방법
EP3509635A1 (de) 2016-09-06 2019-07-17 Vavotar Life Sciences LLC Verfahren zur behandlung von dreifach negativem brustkrebs unter verwendung von zusammensetzungen aus antikörpern und trägerproteinen
RU2021128415A (ru) 2016-09-06 2021-11-08 Мэйо Фаундейшн Фор Медикал Эдьюкейшн Энд Рисерч Композиции с паклитакселом, альбумином и связывающим средством и способы их применения и получения
IL291917A (en) * 2019-10-02 2022-06-01 Sirnaomics Inc Oligonucleotides with nucleoside analogs, compositions comprising same and uses thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0184365B1 (de) * 1984-12-04 1993-08-04 Eli Lilly And Company Tumorbehandlung bei Säugetieren
US6077709A (en) * 1998-09-29 2000-06-20 Isis Pharmaceuticals Inc. Antisense modulation of Survivin expression
US6335194B1 (en) * 1998-09-29 2002-01-01 Isis Pharmaceuticals, Inc. Antisense modulation of survivin expression
US6838283B2 (en) * 1998-09-29 2005-01-04 Isis Pharmaceuticals Inc. Antisense modulation of survivin expression
DK1592793T3 (da) * 2003-02-10 2009-10-26 Santaris Pharma As Oligomeriske forbindelser for modulation af Survivin ekspression

Also Published As

Publication number Publication date
US20070244065A1 (en) 2007-10-18
PL1763356T3 (pl) 2008-12-31
AU2005240020B2 (en) 2011-02-10
PL1913947T3 (pl) 2012-05-31
ES2308488T3 (es) 2008-12-01
EP1763356B1 (de) 2008-07-16
EP1763356A2 (de) 2007-03-21
EP1913947A1 (de) 2008-04-23
CN101683355A (zh) 2010-03-31
DK1763356T3 (da) 2008-10-13
WO2005107771A3 (en) 2006-06-08
AU2005240020A1 (en) 2005-11-17
DK1913947T3 (da) 2012-02-06
SI1913947T1 (sl) 2012-02-29
US20090247611A1 (en) 2009-10-01
PT1913947E (pt) 2012-01-19
US20120022140A1 (en) 2012-01-26
PT1763356E (pt) 2008-09-05
ES2376484T3 (es) 2012-03-14
DE602005008241D1 (de) 2008-08-28
WO2005107771A2 (en) 2005-11-17
CN1950094A (zh) 2007-04-18
JP2007533742A (ja) 2007-11-22
EP1913947B1 (de) 2011-12-28
CA2562750A1 (en) 2005-11-17
MXPA06012132A (es) 2007-01-17
CY1110440T1 (el) 2015-04-29
SI1763356T1 (sl) 2008-12-31
BRPI0509927A (pt) 2007-09-25
ATE401088T1 (de) 2008-08-15
EP2145626A1 (de) 2010-01-20
CY1112397T1 (el) 2015-12-09

Similar Documents

Publication Publication Date Title
CY1112397T1 (el) Συνδυασμενη θεραπεια για την αντιμετωπιση του καρκινου
MX383644B (es) Combinaciones y metodos de administracion de agentes terapeuticos y terapia de combinacion.
EA201000914A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
ATE345130T1 (de) Arylharnstoff-verbindungen in kombination mit anderen zytostatisch oder zytotoxisch wirksamen stoffen zur behandlungen menschlicher krebserkrankungen
MX2010012860A (es) Metodos para tratar cancer del sistema nervioso central.
MX339820B (es) Compuestos oligonucleottidos designados para inhibir el transcrito antisentido natrual apra apolipoproteina-a1.
UA94899C2 (ru) Фиксированное дозирование антител к her
MX2010006519A (es) Metodo para tratar una fractura de hueso con anticuerpos anti-esclerostina.
ATE525070T1 (de) Silbininkomponente zur behandlung von hepatitis
EA200970345A1 (ru) Лечение гипербилирубинемии новорожденных с использованием низких дозировок станнсопорфина
JP2014521342A5 (de)
WO2007130501A3 (en) Combination therapy for treatment of cancer
EA200970436A1 (ru) Соединения карбамата для лечения депрессии
MX2007004955A (es) Metodo de tratar cancer con formulaciones de compeusto de platino a base de lipido administradas intraperitonealmente.
PL1715890T3 (pl) CTGF jako cel dla terapii mikroalbinurii u pacjentów z nefropatią cukrzycową
EA200600989A1 (ru) Применение габоксадола для лечения бессонницы
MXPA05013975A (es) Tratamiento de enfermedades asociadas con amiloide y epileptogenesis.
TW200724158A (en) Combination therapy in the treatment of cancer
RU2007100837A (ru) Способ лечения неврита альвеолярного нерва, вызванного выведением пломбировочного материала в нижнечелюстной канал
MXPA05011568A (es) Uso de irinotecan para el tratamiento de cancer recurrente de mama.
ATE537838T1 (de) Kombinationstherapie mit kloretazin(tm)
MXPA05010216A (es) Uso de ritonavir para el tratamiento de hiperbilirrubinemia no conjugada.
WO2005094803A3 (en) N3-pyridyl-thiamine and its use in cancer treatments
UA110795C2 (uk) Спосіб лікування раку підшлункової залози
BRPI0509805A (pt) processos de tratamento de carcinoma hepatocelular com denspm